Agilon Health Option Alert: Jan, 2027 $7 Calls Sweep (6) near the Bid: 4624 vs 524 OI; Earnings 5/6 After Close [est] 

Agilon Health Option Alert: Jan, 2027 $7 Calls Sweep (6) near the Bid: 4624 @ $1.35 vs 524 OI; Earnings 5/6 After Close [est] Ref=$4.4195

Agilon Health (NYSE:AGL) Stock

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Capital Holding Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analysts adjust price targets and earnings estimates after the tech giant announced the impact of tariffs after its <a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">second-quarter financial results.</a>
 The Apple Analysts: Rosenblatt analyst Barton Crockett downgraded Apple stock from Buy to Neutral and lowered the price target from $263 to $217.
Needham analyst Laura Martin maintained a Buy rating with a $225 price target.
Goldman Sachs analyst Michael Ng maintained a Buy rating and lowered the price target from $259 to $253.
Bank of America analyst Wamsi Mohan maintained a Buy rating and lowered the price target from $240 to $235.
Read Also: <a href="https://www.benzinga.com/tech/25/05/45156890/apple-ceo-tim-cook-warns-of-900-million-tariff-impact-in-june-quarter-expects-majority-of-iphones-sold-in-us-to-be-made-in-india">Apple CEO Tim Cook Warns Of $900 Million Tariff Impact In June Quarter, Expects Majority Of iPhones Sold In US To Be Made In India</a>
Rosenblatt on AAPL: Tariffs and regulatory concerns bring "too much noise" to Apple stock, Crockett said in a recent investor note.
The analyst said Apple has amazing supply chain skill and saw better demand for iPhones than feared in the second quarter, but is not seeing a big enough acceleration in iPhone sales.
"We're left with a well-run company, with OK-muted growth, a need for an exciting new product to reinvigorate growth trading at a premium multiple, in a choppy tariff and regulatory environment," Crockett said.
Crockett said gross margins see more risk in the face of tariffs.
Outside of tariff concerns, Crockett highlights the upgrade and replacement cycle for iPhones is an argument that is fading.
Needham on AAPL: Quarterly results were strong, while guidance was weak, Martin said in a new investor note.
The analyst said Services revenue growth of 12% year-over-year, hitting a record of $26.6 billion, was the biggest highlight in the quarter.
Martin also highlighted a new $100 billion share buyback, dividend increase, margin expansion, Mac revenue growth and iPad revenue growth as key highlights.
The analyst said China revenue, weak guidance, Wearables and iPhone revenue were the items she liked least in the quarter.
Martin said Apple is also seeing lower growth compared to "Big Tech," showing a chart of Apple's growth compared to Amazon.com, Alphabet and Meta Platforms.
Goldman Sachs on AAPL: Ng lowers Apple earnings per share estimates for fiscal 2025, 2026 and 2027 by an average of 3% after the company's second-quarter results and updated guidance.
The analyst said Apple beat earnings per share in the quarter on Services strength, but product margins now face tariff headwinds.
"AAPL did not provide segment revenue growth commentary likely reflecting uncertainty related to the macro environment, consumer spending, trade policy, and App Store policy changes," Ng said.
Apple guided for a $900 million tariff-related impact in the third quarter, but Ng said that tariff pressure could continue. &nbsp;
"We expect tariff-related headwinds to increase in future quarters, given that inventory costs likely will rise and F3Q represents the smallest iPhone quarter."
The analyst said Apple faces risks like weakened consumer demand, supply chain disruptions, increasing competition and regulatory risks.
Bank of America on AAPL: Tariffs create gross margin headwinds, Mohan said in a new investor note.
The analyst said Apple stock is a buy on earning resiliency and strong capital returns, but near-term uncertainty around tariffs could put pressure on shares. &nbsp;
"The net impact to estimates still remains relatively low despite the impact of tariffs and in our opinion, the ability to navigate sustained tariffs should improve over time," Mohan said.
Mohan said Apple's product gross margins have trended lower year-over-year for five consecutive quarters.
AAPL Price Action: Apple stock is down 3.91% to $205.02 on Friday versus a 52-week trading range of $169.21 to $260.09. Apple stock is down 15.9% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/05/45157565/dan-ives-raises-apple-price-target-to-270-says-worst-case-scenario-off-the-table-for-iphone-tariffs-as-tim-cook-reveals-made-in-india-move">Dan Ives Raises Apple Price Target To $270, Says &#8216;Worst Case Scenario&#8217; Off The Table For iPhone Tariffs As Tim Cook Reveals Made In India Move</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Downgrades

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

AAPL

Apple Stock Faces 'Tariff-Related Headwinds': 4 Analysts Break Down Q2 Results, What's Next

RBC Capital analyst Brad Erickson maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and lowers the price target from $235 to $230.

News

AMZN

RBC Capital Maintains Outperform on Amazon.com, Lowers Price Target to $230

The FDA application is based on results from OASIS 4, a 64-week phase 3 randomized, controlled trial evaluating the efficacy and safety of once-daily oral&nbsp;semaglutide 25 mg versus placebo in 307 adults with obesity (BMI &gt;/= 30 kg/m2) or overweight (BMI &gt;/= 27 kg/m2) with one or more comorbidities.1,3 Patients with diabetes were excluded.1,3
OASIS 4 included a 64-week treatment period including a 12-week dose escalation, and a 7-week off-treatment follow-up period.1,3 In total, 307 participants were randomized 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks.1,3
The FDA action date to decide on the&nbsp;Wegovy&#xAE; oral formulation NDA will be in Q4 2025.2

Biotech

General

The FDA Action Date To Decide On The Wegovy Oral Formulation NDA Will Be In Q4 2025

American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) shares are trading higher on Friday <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45163511/aam-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">after reporting first quarter results</a>.
The firm reported quarterly adjusted earnings per share of 9 cents, beating the analyst consensus estimate of 2 cents.
Quarterly sales of $1.41 billion (down 12% year over year) missed the street view of $1.43 billion. Sales for the first quarter of 2025 were negatively impacted by lower volumes overall.     
The company reported gross profit of $173.9 million, down from $198.5 million a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44963985/automakers-are-struggling-with-tariffs-and-ev-competition-say-analysts" rel="noreferrer noopener">Automakers Are Struggling With Tariffs And EV Competition, Say Analysts</a>
American Axle&#8217;s adjusted EBITDA fell on a year-over-year basis to $177.3 million from $205.6 million a year ago.
The company&#8217;s net cash provided by operating activities for the first quarter was&nbsp;$55.9 million&nbsp;as compared to&nbsp;$17.8 million&nbsp;in the year-ago period.
The company exited the quarter with cash and equivalents $549.2 million.
Outlook: American Axle &amp; Manufacturing lowered its 2025 sales forecast to $5.65 billion–$5.95 billion from $5.80 billion–$6.05 billion, compared with the $5.82 billion estimate.
&#8220;AAM will stay focused on managing factors under our control while operating in an uncertain geopolitical trade policy environment. In addition, we continue to make excellent progress on our transformational Dowlais combination,&#8221; said CEO David C. Dauch.
Price Action: American Axle shares are trading higher by 4.87% to $3.98 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/05/45150864/trade-profitably-on-cooling-energy-earnings" target="_blank" rel="noreferrer noopener">Trade Profitably On Cooling Energy Earnings</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

What's Going On With American Axle Stock Today?

<ul>
<li>Novo Nordisk hopes to expand Wegovy&#xAE; label by becoming the first GLP-1 treatment for obesity in a pill</li>
<li>The FDA filing is based on the results of the phase 3 OASIS 4 trial that evaluated oral semaglutide 25 mg in adults with obesity or overweight1</li>
<li>Novo Nordisk continues to build on 100-year-plus legacy of science and innovation</li>
</ul>
PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo&nbsp;Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of&nbsp;Wegovy&#xAE; (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease.2 If approved, Wegovy&#xAE; would become the first oral formulation of a GLP-1 indicated for chronic weight management.

Novo Nordisk Announces The FDA Accepts Filing Application For Oral Semaglutide 25mg, Which If Approved, Would Be The First Oral GLP-1 Treatment For Obesity

RBC Capital analyst Leonid Timashev maintains Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Sector Perform and raises the price target from $39 to $40.

ALKS

RBC Capital Maintains Sector Perform on Alkermes, Raises Price Target to $40

RBC Capital analyst Brad Erickson maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Sector Perform and lowers the price target from $160 to $140.

ABNB

RBC Capital Maintains Sector Perform on Airbnb, Lowers Price Target to $140

Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Equal-Weight and lowers the price target from $146 to $137.

Wells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $137

RBC Capital analyst Deane Dray maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Outperform and raises the price target from $194 to $201.

RBC Capital Maintains Outperform on AMETEK, Raises Price Target to $201

Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Overweight and lowers the price target from $26 to $19.

ARVN

Wells Fargo Maintains Overweight on Arvinas, Lowers Price Target to $19

Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for people living with MASH <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">(metabolic dysfunction-associated steatohepatitis)</a>.
&#8220;Semaglutide 2.4 mg represents a therapeutic advancement for patients living with MASH, addressing a critical unmet medical need,&#8221; <a href="https://www.newswire.ca/news-releases/health-canada-accepts-semaglutide-2-4-mg-a-glp-1ra-treatment-for-mash-as-a-supplemental-new-drug-submission-under-the-priority-review-policy-881682700.html#:~:text=Semaglutide%20injection%202.4%20mg%20is,%E2%89%A5%2027%20kg%2Fm2.&amp;text=Semaglutide%20is%20not%20approved%20in%20Canada%20for%20the%20treatment%20of%20MASH." target="_blank" rel="noreferrer noopener">says</a> Vince Lamanna, President of Novo Nordisk Canada Inc. &#8220;Health Canada&#8217;s acceptance of the Semaglutide 2.4 mg submission for review brings us one step closer to providing the first treatment option for eligible people living with MASH.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence</a>
In November 2024, Health Canada approved Wegovy (semaglutide injection) to <a href="https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2024/wegovy-non-fatal-mi-indication-announcement-press-release-112624.pdf" target="_blank" rel="noreferrer noopener">reduce</a> the risk of non-fatal myocardial infarction (MI) in adults with established cardiovascular disease and a  BMI equal to or greater than 27 kg/m2.
It was the first Health Canada-approved treatment to support both chronic weight management and to reduce the risk of non-fatal MI.
MASH is a chronic, progressive metabolic disease affecting the liver.
Among people who are overweight or have obesity, about one in three also have MASH.
Excess fat can build up in the liver, which, over time, can lead to inflammation and severe scarring of the liver.
By 2030, the prevalence of MASH in the Canadian general population is estimated to increase from 5.2% to 6.5%.
In&nbsp;Canada, the number of deaths is expected to double in people living with MASH by 2030.
On Thursday, Novo Nordisk announced that&nbsp;CVS Health Inc's&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;CVS Caremark, a Pharmacy Benefit Manager (PBM), decided that Wegovy&nbsp;(semaglutide) injection 2.4 mg will soon be the preferred&nbsp;GLP-1&nbsp;medicine on its largest commercial&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45147328/cvs-caremark-to-place-novo-nordisks-wegovy-on-preferred-coverage-for-glp-1-weight-loss-treatment" rel="noreferrer noopener">template formularies</a>.
This change will take effect on&nbsp;July 1, 2025.&nbsp;
In February, the FDA confirmed that all doses of Wegovy were available. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for <a href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" target="_blank" rel="noreferrer noopener">self-paying patients</a>.
More recently, the Wegovy&nbsp;savings offer was updated, allowing eligible self-paying patients to get the&nbsp;$499-per-month price at their local pharmacy.
On Tuesday,&nbsp;Novo Nordisk and&nbsp;Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/45074872/hims-hers-stock-surges-as-it-collaborates-with-novo-nordisk-to-sell-weight-loss-drug-wegovy-on-its-platform" rel="noreferrer noopener">long-term collaboration</a>.
The company said that individuals may be prescribed Wegovy at a single, unified price starting at $599 per month. The offering is available this week on the Hims &amp; Hers platform.
This new offering builds on Hims &amp; Hers&#8217; existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
Price Action: NVO stock is up 5.5% at $69.21at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45170554/dupont-delivers-strong-q1-highlights-electronics-spin-off-confirms-2025-guidance" target="_blank" rel="noreferrer noopener">DuPont Delivers Strong Q1, Highlights Electronics Spin-Off, Confirms 2025 Guidance</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Why Is  Novo Nordisk Stock Trading Higher On Friday?

RBC Capital analyst Matthew Swanson maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Outperform and lowers the price target from $100 to $85.

RBC Capital Maintains Outperform on Trade Desk, Lowers Price Target to $85

Wells Fargo analyst Michael Kaye maintains PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) with a Equal-Weight and lowers the price target from $14 to $13.

Wells Fargo Maintains Equal-Weight on PennyMac Mortgage IT, Lowers Price Target to $13

RBC Capital analyst Matthew Swanson maintains PubMatic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) with a Outperform and lowers the price target from $17 to $14.

PUBM

RBC Capital Maintains Outperform on PubMatic, Lowers Price Target to $14

Amneal Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) reported first-quarter 2025 adjusted EPS of 21 cents, up from 14 cents a year ago, and beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 15 cents</a>.
The company reported sales of $695.42 million, up 5% year-over-year, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45160748/amneal-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">consensus of $715.49 million</a>.
Affordable Medicines&#8217; (previously Generics&#8217;) net revenue increased 6%, driven by the strong performance of its complex product portfolio and new product launches.
Specialty net revenue increased by 3%, driven by key branded products, including Crexont and Unithroid.
AvKare net revenue increased by 6%, driven by growth in the government label sales channel.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/25/04/44673049/amneals-combination-drug-shows-improved-sleep-quality-in-parkinsons-disease-patients" rel="noreferrer noopener">Amneal&#8217;s Combination Drug Shows Improved Sleep Quality In Parkinson&#8217;s Disease Patients</a>
The company&#8217;s net income was $12 million in the first quarter of 2025. In the first quarter of 2024, it reported a net loss of $92 million, reflecting a legal settlement charge of $94 million.
Adjusted EBITDA was $170 million, an increase of 12% compared to the first quarter of 2024, reflective of strong revenue performance, higher gross margin and operating expense leverage.
Guidance: Amneal reaffirms 2025 revenue guidance of $3 billion—$3.1 billion and <a href="https://www.benzinga.com/general/health-care/25/02/44040038/generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars" target="_blank" rel="noreferrer noopener">adjusted EPS of 65-70 cents</a>. Compare that to the consensus of $3.03 billion and 68 cents, respectively.
The company expects 2025 adjusted EBITDA of $650 million—$675 million. It also has operating cash flow of up to $285 million and capital expenditures of approximately $100 million.
In March, the U.S. Food and Drug Administration (FDA) accepted for review Amneal and mAbxience&#8217;s partnered Biologics Licensing Application (BLA) for two proposed denosumab biosimilars referencing Prolia&nbsp;and Xgeva.
The FDA has assigned a target action date in the fourth quarter of 2025. Currently, Amneal commercializes three biosimilars in the U.S., with the two denosumab biosimilar candidates representing its next potential biosimilar launches. Additionally, three more biosimilars are in development. This positions Amneal to have a portfolio of six biosimilars across eight <a href="https://www.benzinga.com/pressreleases/25/03/b44093926/amneals-bla-submissions-for-two-denosumab-biosimilars-accepted-for-review-by-u-s-fda" target="_blank" rel="noreferrer noopener">product presentations by 2027</a>.
Price Action:&nbsp;AMRX stock is down 1.16% at $7.65 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45164566/exxon-mobil-q1-profit-tops-forecasts-despite-revenue-miss-slashes-costs-by-127-billion-more" target="_blank" rel="noreferrer noopener">Exxon Mobil Q1: Steady Production, Focus On Cost Cuts And Stock Buyback</a></li>
</ul>

AMRX

Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed

Wells Fargo analyst Ken Gawrelski maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $100 to $104.

Wells Fargo Maintains Underweight on Airbnb, Raises Price Target to $104

Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) posted upbeat fiscal third-quarter results but issued weak sales guidance <a href="https://www.benzinga.com/quote/TEAM/earnings">for the fourth quarter on Thursday.</a>
Atlassian reported third-quarter revenue of $1.36 billion, beating analyst estimates of $1.35 billion. The collaboration and productivity software provider reported third-quarter adjusted earnings of 97 cents per share, beating analyst estimates of 87 cents per share.
"Our long-term investments in building a world-class Cloud platform have enabled us to advance the Atlassian System of Work and bring Rovo's powerful AI capabilities to the center," said Mike Cannon-Brookes, co-founder and CEO of Atlassian.
Atlassian said it expects fourth-quarter revenue to be in the range of $1.35 billion to $1.36 billion versus estimates of $1.42 billion. The company anticipates cloud revenue growth of 23% and data center growth of 16.5% on a year-over-year basis in the fourth quarter. Marketplace and other revenue is expected to be approximately flat.
Atlassian also guided for full-year 2025 revenue of $5.19 billion versus estimates of $5.18 billion, according to Benzinga Pro.
Atlassian shares fell 7.2% to trade at $212.42 on Friday.
These analysts made changes to their price targets on Atlassian following earnings announcement.
<ul>
<li>Piper Sandler analyst Rob Owens reiterated Atlassian with an Overweight rating and lowered the price target from $365 to $300.</li>
<li>Macquarie analyst Steve Koenig maintained the stock with an Outperform rating and lowered the price target from $270 to $250.</li>
<li>Canaccord Genuity analyst David Hynes maintained Atlassian with a Buy and cut the price target from $300 to $255.</li>
<li>Raymond James analyst Adam Tindle reiterated Atlassian with an Outperform rating and lowered the price target from $330 to $300.</li>
<li>Stephens &amp; Co. analyst Brett Huff maintained the stock with an Equal-Weight rating and lowered the price target from $255 to $221.</li>
<li>Wells Fargo analyst Michael Turrin maintained Atlassian with an Overweight rating and lowered the price target from $330 to $315.</li>
</ul>
Considering buying TEAM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="561" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02141718/image-30-1024x561.png" alt="" class="wp-image-899809" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02141718/image-30-1024x561.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02141718/image-30-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02141718/image-30-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02141718/image-30.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

TEAM

These Analysts Cut Their Forecasts On Atlassian After Q3 Results

Wells Fargo analyst Ken Gawrelski maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Overweight and raises the price target from $158 to $168.

RDDT

Wells Fargo Maintains Overweight on Reddit, Raises Price Target to $168

Wells Fargo analyst Steven Cahall maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Overweight and raises the price target from $93 to $100.

ROKU

Wells Fargo Maintains Overweight on Roku, Raises Price Target to $100

Wells Fargo analyst Michael Brown maintains Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Equal-Weight and raises the price target from $19 to $20.

Wells Fargo Maintains Equal-Weight on Blue Owl Capital, Raises Price Target to $20

Press Releases

agilon health to Participate at 2024 Wolfe Research Healthcare Conference

agilon health Reports Third Quarter 2024 Results

agilon health Reports ACO REACH Model Results for 2023 Performance Year

Legal

Agilon Health, Inc, B. Riley Financial, Target Corporation, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

agilon health Sets Date to Report Fourth Quarter and Full Year 2024 Financial Results

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of agilon health, inc. (NYSE: AGL) and Encourages Long-Term Investors to Contact the Firm

agilon health to Participate in TD Cowen's 45th Annual Health Care Conference

agilon health Reports Fourth Quarter and Full Year Fiscal 2024 Results

agilon health Sets Date to Report First Quarter 2025 Financial Results

agilon health to Participate in BofA Securities 2025 Health Care Conference

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Agilon Health

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL